PD-1/PD-L1-IN-10 - 10mM in DMSO , CAS No.2487550-41-2

CAS: 2487550-41-2 Cat. No.: P655595 Molecular Weight: 581.62 PubChem CID: 156599565
AVAILABLE TO ORDER
GRADE & PURITY 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
P655595-1ml
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$286.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacy

In Vitro

PD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro even at the low concentration of 1 nM. PD-1/PD-L1-IN-10 (compound B2) does not affect cell viability of LLC cells and lymph node T-cells. PD-1/PD-L1-IN-10 (compound B2, 0-100 nM) stabilizes the PD-L1 protein in mouse Lewis lung carcinoma (LLC) cells. In particular, PD-1/PD-L1-IN-10 (compound B2) maintains the PD-L1 stability in a dose-dependent manner at 58 °C. Suggesting that PD-1/PD-L1-IN-10 (compound B2) could enter LLC cells and then directly binds to the PD-L1 protein. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PD-1/PD-L1-IN-10 (compound B2, 5 mg/kg, intragastric gavage) exhibits potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model. PD-1/PD-L1-IN-10 (compound B2) effectively blocks tumor cell proliferation and induces apoptosis in LLC tumor tissues. . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: LLC tumor-bearing mice . Dosage: 2, 5 mg/kg. Administration: i.g., qd., for 21 days Result: Significantly suppressed the growth of the tumor in a dose-dependent manner compared with the vehicle group.

IC50& Target:IC50: 2.7 nM (PD-1/PD-L1)

Specifications

Specifications & Purity
10mM in DMSO
Biochemical and Physiological Mechanisms
PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacy.
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Names and Identifiers
PubChem CID 156599565
Molecular Weight 581.62

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.